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Novel tricyclic N-benzylated chroman-4-one tetrahydropyrimidine derivatives have been prepared
through a multi-component reaction between various 2-substituted chroman-4-one derivatives, N-
methylenebenzylamine and a catalytic amount of proline under mild reaction conditions. The tricyclic
structure of 1a was determined by NMR spectroscopy and conﬁrmed by X-ray crystallography. An ad-
ditional product, 2a, was isolated from the reaction mixture and its structure and conformation were
determined by a combination of theoretical (Monte Carlo conformational search) and NMR-based (NOE
and 3JHH couplings) conformational analysis. The NMR analysis revealed one preferred geometry for 1a
and 2a in CHCl3 solution.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Substituted chroman-4-ones are regarded as common struc-
tures for drug design.1 Along with related, higher order oxygen-
containing ring systems, they are frequently found in plants and
marine organisms2 and have been shown to possess antioxidant,3
antiviral4 and antibacterial5 activities. Protocols for the prepara-
tion of substituted chromones and chroman-4-ones have been
developed by our group with the most recent progress being the
incorporation of a carboxy functionality in the 6-position6,7 and an
amino group in the 3-position (Fig.1).7e9 Such chromone/chroman-
4-ones have been designed as potential b-turn peptidomimetics.9
As an extension of these studies we explored the use of the
Mannich reaction to introduce an aminomethyl group in the 3-s a potential b-turn mimetic.
1; fax: þ46 49 31 772 1394;
elyi), luthman@chem.gu.se
Y-NC-ND license.position of the 2-alkyl-chroman-4-one scaffold. However, this re-
action did not result in the desired product, instead tricyclic chro-
man-4-one derivatives were isolated. Herein, we report the
synthesis and conformational analysis of these novel chroman-4-
one tetrahydropyrimidines.2. Results and discussion
As found in the present study a proline-mediated Mannich re-
action resulted in the unexpected formation of two novel tricyclic
derivatives 1 and 2 (Fig. 2). This fact indicates a yet unexplored
potential of the amino acid-catalyzed Mannich reaction. The new
compounds are expected to be of interest due to their high struc-
tural similarity to derivatives with signiﬁcant pharmacological ac-
tivities.10,11 Examples of such compounds are the amine containing
tricyclic chroman-4-one analogues of 3, which exhibit anti-in-
ﬂammatory12 and antiplatelet13 activities (Fig. 2) whereas the
Biginelli analogue 414 belongs to a type of structures shown to act as
calcium channel blockers.152.1. Synthesis
For the synthesis of the title compounds, the racemates of 8-
bromo-6-chloro-2-alkyl substituted chroman-4-ones 5aec
(Scheme 1) were used. They were synthesized via a microwave
promoted two-component reaction using commercially available
Fig. 2. The novel tricyclic chroman-4-one derivatives 1 and 2 along with the struc-
turally related compounds 3 and 4, which were reported to exhibit promising phar-
macological activities.
Fig. 3. The crystal structure of the tricyclic derivative 1a.
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presence ofN,N-diisopropylamine (DIPA) in ethanol.8 As L-proline is
known to efﬁciently catalyze asymmetric Mannich reactions16e18 it
was chosen for the corresponding reactions of derivatives 5aec.
Interestingly, reacting 5a with an excess of N-methylenebenzyl-
amine19 (5 equiv) and a catalytic amount of L-proline (0.3 equiv) in
DMSO at 50 C for 48 h afforded instead the novel tricyclic de-
rivative 1a in 52% yield (Scheme 1). The chroman-4-one 5b
substituted with a phenethyl group in the 2-position and 5c with
a considerably smaller 2-methyl substituent were also examined
(Scheme 1). Applying the identical reaction conditions, an excess of
N-methylenebenzylamine in DMSO in the presence of a catalytic
amount of L-proline, the products 1b and 1c were formed but in
lower yields (26% and 15%, respectively) as compared to 1a. An
attempt to synthesize a derivative with a 2-phenyl substituent was
unsuccessful.Scheme 1. The L-proline catalyzed formation of tricyclic derivatives 1aec.
Scheme 2. Proposed mechanism for the synthesis of derivatives 1aec.The structure of 1awas determined byHMBC, HSQC and NOESY-
based NMR spectroscopic investigation and was conﬁrmed by X-
ray crystallography (Fig. 3). Remarkably, the bulky substituent in
the 5-position prefers to adopt an axial orientation.
Compounds 1aec are formed via a Biginelli-type mechanism.15
Proline is suggested to catalyze the enolization of the chroman-4-
one (Scheme 2) instead of mediating enamine formation, which
was previously proposed for L-proline.16 This conclusion is based onexperiments using additional secondary amine sources such as
DIPA and pyrrolidine, which were shown to mainly react as nu-
cleophiles leading to ring opening of the chroman-4-one ring
(according to 1H NMR spectroscopic analysis of the crude reaction
mixture). In addition, upon heating a mixture of L-proline and
chroman-4-one 1a at 50 C no enamine formation was observable
by 1H NMR spectroscopy. Hence, in the proposed mechanism the
enol of 5aec attacks the preformed N-methylenebenzylamine
providing the Mannich product as an intermediate. The subsequent
nucleophilic attack of the newly formed amino function on a sec-
ond N-methylenebenzylamine gives the aminal of which one
amino group attacks the carbonyl functionality in the chroman-4-
one. Subsequent dehydration provides the tetrahydropyrimidine
ring and thus the ﬁnal product.
M. Friden-Saxin et al. / Tetrahedron 68 (2012) 7035e7040 7037In an attempt to optimize the yield of the tricyclic derivatives
1aec a series of reaction conditions were examined. The use of
smaller amounts of N-methylenebenzylamine, shorter reactions
times or higher temperatures (20 min or 2 h at 80, 120 or 150 C
under microwave irradiation) resulted in lower conversions. Simi-
lar observations were made upon variation of the chiral catalysts
(sarcosine, L-pipecolic acid), the use of achiral catalysts (glycine,
DIPA, DIPEA or pyrrolidine), racemic catalyst (D/L-proline) or alter-
ation of solvents (THF or DMF). Neither the change of substrate
structure by removal of substituents or by introduction of electron
donating (OMe) or electron withdrawing (NO2 or Cl) groups in the
6-position of the chroman-4-one resulted in improved yields.
Further attempts on reacting 5a with electrophiles such as N-
methylene p-anisidine imine provided only traces of the Mannich
product along with numerous impurities. Using dibenzyl imine as
the electrophile resulted only in recovered starting material.
The isolated yields of derivatives 1a-cwere moderate due to the
competing formation of additional heterocyclic products. For ex-
ample, the synthesis of 1a also yielded 2a in 7% isolated yield
(Scheme 3). As expected the formation of analogous products was
detected also in the synthesis of 1b and 1c (2b and 2c in 26% and
23% yields, respectively). Compound 2awas found to have identical
molecular weight to 1a, but showed a different 1H NMR spectrum
and chromatographic behaviour. Therefore additional HMBC and
NOESY-based NMR spectroscopic investigations were performed,
as described in detail below.Scheme 3. The L-proline-mediated formation of tricyclic derivatives 1aec and 2aec.
Scheme 4. A proposed mechanism for the formation of compounds 2aec.The mechanism for the formation of compounds 2aec is sug-
gested to occur via a nucleophilic attack by benzylamine on the
chroman-4-one ring system as shown in Scheme 4. Benzylamine is
most likely formed by partial hydrolysis of N-methylenebenzyl-
amine. However, using dry DMSO as the solvent and molecular
sieves (4A) or MgSO4 as drying agents did not prevent the de-
composition of N-methylenebenzylamine and hence the formation
of the heterocyclic products 2aec.
2.2. Conformational analysis of 1a and 2a
Small molecules encompassing ﬂexible bonds commonly exist
in solution as a mixture of rapidly interconverting conformers.20
Their solution structure usually cannot be correctly represented
by a single averaged structure, but is preferably described as the
probability-weighted ensemble of several conformations present in
solution. The determination of such ensembles is possible, although
not yet extensively carried out, by deconvolution of their time-
averaged spectroscopic data.21,22 For elucidation of the structure
of 2a as well as the available conformational space of the tricyclic
backbones of 1 and 2 a combined computational and NMR spec-
troscopic approach was utilized. A Monte Carlo conformational
search followed by molecular mechanics minimization of thegenerated structures was performed using the OPLS-2005 all atom
force ﬁeld23 and the Born solvation model for chloroform,24 as
implemented in the MacroModel program (v. 9.7).25
The mixed torsions/low mode method was employed and con-
formations within 21 kJ/mol from the global minimum were kept.
This protocol yielded two distinct conformational families for 1a and
2a. Because of the uncertainty and force ﬁeld dependency of the
energies of computationally derived conformations, the predicted
populations of theoretical ensembles do not necessarily represent
the molecular structure present in solution,20,26,27 yet allow their
determination when utilized in combination with experimental
data.20,22 Accordingly, the set of structures derived by the confor-
mational analysis was evaluated in a subsequent NAMFIS (NMR
analysis of molecular ﬂexibility in solution) analysis.28 Distances
were determined by acquisition of NOE-buildups with ﬁve mixing
times (100, 150, 200, 250, and 400 ms) using the initial rate ap-
proximation,29 whereas scalar couplings were obtained from stan-
dard 1H and P.E. COSY30 spectra. Despite the fewavailable protons on
the tricyclic backbone of 1a and2a, a sufﬁcient number of NOEswere
observed fordescription of the orientation of theirﬂexible fragments
(Fig. 4). As enantiomeric mixtures yield a single set of NMR signals,
the conformational analysis of 1a and 2a was carried out without
chiral separation. Assignment of the diastereotopic CH2 protons was
based on relative NOE intensities and corresponded to the expected
Fig. 4. NOE correlations observed in NMR spectra of 1a and 2a in chloroform. Two and
six additional J-couplings, respectively, are described in Supplementary data.
Fig. 6. Alignment of a modiﬁed structure of the tricyclic derivative 6 and a type VIII
b-turn (F(iþ1)¼60 , j(iþ1)¼30 , F(iþ2)¼120 and j(iþ2)¼120).31
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(Fig. 4). The solution ensembleswere determined by identiﬁcation of
the geometries truly present in solution from the theoretically pre-
dicted conformational pool using experimental selection criteria.
Hence, 8 and 11 possibly time-averaged NMR-derived distances and
dihedral angleswere used to deconvolute the conformational pool of
1a and 2a using the NAMFIS protocol. Details of the analysis, in-
cluding the comparison of the observed and the calculated distances
are given in Supplementary data.
The analysis of 1a indicated one preferred conformation in so-
lution. This geometry showed dihedral angles corresponding to
those observed in the solid state by X-ray analysis including also the
axially positioned 5-substituent (Fig. 5a).
Compound 2awas revealed to also prefer a single conformation
(Fig. 5b) in which the large 4-substituent is equatorially oriented.
Thus, the reﬁnement revealed that only one of the computationally
predicted conformational families exists in solution for 1a and 2a. It
should be underlined that application of the NAMFIS protocol en-
sures that the identiﬁed geometries are the real solution structures
and therefore are pharmacologically relevant.
Given our aim to use chroman-4-one/chromone scaffolds as
novel mimetics of bioactive peptides it was especially interesting to
ﬁnd that the tricyclic cores of 1a and 2a efﬁciently mimic a native
type VIII b-turn (Fig. 6; see the Experimental section for details on
the calculations). Their Cl- and Br-substitutions provide possibili-
ties for selective functionalization through Pd-mediated cross-
coupling reactions,6 and thereby allow broad applicability. How-
ever, any further investigations in this direction are outside the
scope of the present study.
3. Conclusions
A one-pot proline catalyzed synthetic route to novel chroman-4-
one tetrahydropyrimidine derivatives 1aec and 2aec has been
developed. The reactions are proposed to proceed through an L-Fig. 5. (a) The solution structure of the core of 1a (yellow) overlapped with its X-ray
derived conformation (green). (b) The solution conformation of the tricyclic core of 2a,
as identiﬁed by NAMFIS analysis.proline-mediated enolization mechanism. Depending on the
identity of the 2-substituent of the chroman-4-one products were
obtained in varying yields. Combined NMR spectroscopic and the-
oretical conformational analysis of 1a and 2a revealed the presence
of a single geometry in solution, which for 1a was revealed to be
identical to its solid state (X-ray) structure. The obtained products
are of considerable interest due to their potential pharmaceutical
applicability. Their use as potential scaffolds for type VIII b-turn
peptidomimetics will be further explored.4. Experimental section
4.1. General
Commercially available chemicals were used without prior pu-
riﬁcation. The reactions were monitored by thin-layer chromatog-
raphy (TLC) on silica plated aluminium sheets (Silica gel 60 F254, E.
Merck). Flash chromatography was performed on silica gel 60
(0.040e0.063 mm, manually or using a Biotage SP4 Flashþ in-
strument). Microwave reactions were carried out using a Biotage
Initiator Sixty with ﬁxed hold time modus in 2e5 mL or
10e20 mL cappedmicrowave vials. IR was recordedwith a ChiralIR-
2x from BioTools. Every compoundwas dissolved in 0.5 mL CDCl3.
High-resolution mass spectral analysis (Q-TOF-MS) was performed
at Stenhagen Analyslab AB, Gothenburg, Sweden. Elemental anal-
yses were performed at Kolbe Mikroanalytisches Laboratorium,
M€ulheim and der Ruhr, Germany.
NMR spectra were recorded on JEOL GX-270 (400 MHz) or
Varian Unity Innova (800 MHz) spectrometer. Assignments of sig-
nals of derivatives 1a and 2a were made using HMBC, HSQC and
NOESY spectra. The samples were dissolved in CDCl3. Chemical
shifts are reported in parts per million with the solvent residual
peak as internal standard: CDCl3 [CHCl3 dH 7.26, CDCl3 dC 77.0]. The
NOE buildup studies were performed on 0.5 mmol/dm3 solutions at
mixing times of 100, 150, 200 and 250 and 400 ms. Distances were
calculated with a reference distance of 1.78A for geminal protons.
NOE peak intensities were calculated using normalization of both
cross-peaks with both diagonal peaks according to ([xpeak1x-
peak2])/([diagpeak1diagpeak2])0.5. Five mixing times yielding
M. Friden-Saxin et al. / Tetrahedron 68 (2012) 7035e7040 7039a linear (r2>0.95) initial NOE rate were used to estimate the sij
buildup rates according to the equation rij¼rref(sref/sij)(1/6), where rij
is the distance between protons i and j and sij is the normalized
intensity obtained from NOE experiments. The 3JHH couplings were
derived from E.COSY experiments.
The computer based studies were performed using the Macro-
Model program (v. 9.7)25 as implemented in Maestro (v. 9.0). The
conformational search for 1a and 2a was performed using the
OPLS-2005 force ﬁeld and the Born solvation model for chloroform.
The number of torsional rotations were restricted to 36 and the cut
off was set to 0.5A. The conformational search was performed
using the mixed torsions/low mode method with 5000 steps. The
minimization method used was PRCG (Polak-Ribiere Conjugate
Gradient) with amaximum of 500 iterations. Conformations within
21 kJ/mol from the global minimumwere retained. This resulted in
2000 (1a) and 1351 (2a) conformations, respectively. The confor-
mations were subsequently re-minimized using TNCG (truncated
Newton conjugate gradient) using the same criteria as described
above. The repeated minimization gave 162 (1a) and 349 (2a)
conformations, respectively, where conformations within 21 kJ/mol
from the global minimum were retained.
4.2. Synthesis of chroman-4-ones 5aec
4.2.1. 8-Bromo-6-chloro-2-(2-(1-tosyl-1H-indol-3-yl)ethyl)-chro-
man-4-one (5a). The chroman-4-one was synthesized according
to the procedure reported by Friden-Saxin et al.8 To an ethanolic
solution (2.5 mL) of 30-bromo-50-chloro-20-hydroxyacetoph
enone (0.250 g, 1.002 mmol, 1 equiv) 3-(1-tosyl-1H-indol-3-yl)
propanal (0.146 mL, 1.10 mmol, 1.1 equiv) and DIPA (0.154 mL,
1.10 mmol, 1.1 equiv) were added. The reaction was run in a mi-
crowave cavity for 1 h at 170 C. The reaction mixture was di-
luted with Et2O and the phases were separated. The organic
phase was washed with NaOH (aq, 1%), HCl (aq, 0.1 M), water and
brine. The organic phase was dried over anhydrous MgSO4, ﬁl-
tered and concentrated under vacuum. The obtained crude
product was puriﬁed by ﬂash chromatography using EtOAc/
heptane (2.5%) yielding 5a as an orange oil (0.31 g, 88%) as
previously reported.8
4.2.2. 8-Bromo-6-chloro-2-phenethylchroman-4-one (5b). 30-
Bromo-50-chloro-20-hydroxyacetophenone (1.38 g, 5.54 mmol) was
reacted with 3-phenylpropanal (2.00 g, 6.10 mmol) and DIPA
(0.856 mL, 6.10 mmol) in ethanol (15 mL) following the general
procedure. Puriﬁcation by ﬂash chromatography using toluene/
heptane (50%) afforded 5b as a yellow solid (2.28 g, 74%) as pre-
viously reported.8
4.2.3. 8-Bromo-6-chloro-2-methylchroman-4-one (5c). 30-Bromo-
50-chloro-20-hydroxyacetophenone (1.51 g, 6.05 mmol), acetalde-
hyde (0.373 mL, 6.61 mmol) and DIPA (0.932 mL, 6.61 mmol) were
reacted following the general procedure. Puriﬁcation by ﬂash
chromatography using EtOAc/heptane (1:9) gave 5c (0.47 g, 28%) as
a yellow oil. Rf¼0.77 (5% EtOAc/heptane); IR 3158, 2906, 2362,
2332, 1819 cm1; 1H NMR (400 MHz) d 7.80 (d, J¼2.6 Hz, 1H), 7.70
(d, J¼2.6 Hz, 1H), 4.72e4.62 (m, 1H), 2.78e2.65 (m, 2H), 1.59 (d,
J¼6.2 Hz, 3H); 13C NMR (100 MHz) d 190.4,156.7, 138.4,126.8,125.8,
122.1, 112.5, 75.4, 43.7, 20.7; HRMS (Q-TOF-MS) [MþH]þ, calcd for
C10H9BrClO2: 274.9474, found: 274.9429.




2,3,4,5-tetrahydro-1H-chromeno[4,3-d]pyrimidine (2a). Chroman-4-one 5a (0.100 g, 0.179 mmol, 1 equiv) was dissolved in DMSO
(2.5 mL). N-Methylenebenzylamine19 (0.106 g, 0.895 mmol,
5 equiv) and L-proline (6.18 mg, 0.054 mmol, 0.3 equiv) were
added. The reaction mixture was stirred at 50 C for 48 h. The re-
actionwas quenchedwith NH4Cl (satd, aq) followed by the addition
of EtOAc. The phases were separated and the aqueous phase was
extracted with EtOAc. The combined organic phases were washed
three times with brine, dried over anhydrous MgSO4, ﬁltered and
the solvent was removed under vacuum. Puriﬁcation by ﬂash
chromatography using a gradient of heptane/toluene (20%) gave 1a
(72 mg, 52%) and 2a (10 mg, 7%) as orange oils.
4.3.1.1. Compound 1a. Rf¼0.4 (5% EtOAc/toluene); IR 3160, 2362,
2337, 1822, 1794, 1453, 1375 cm1; 1H NMR (400 MHz) d 8.03 (d,
J¼8.2 Hz, 1H), 7.75 (d, J¼8.2 Hz, 2H), 7.51e7.16 (m, 18H), 4.68e4.61
(m, 1H), 4.03e3.92 (m, 2H), 3.59e3.47 (m, 3H), 3.32 (d, J¼11.1 Hz,
1H), 3.19 (d, J¼16.9 Hz, 1H), 3.09e2.85 (m, 3H), 2.33 (s, 3H),
2.19e2.06 (m, 1H), 1.93e1.82 (m, 1H); 13C NMR (100 MHz) d 148.2,
144.6, 138.2, 137.7, 135.3, 135.2, 134.7, 131.2, 130.8, 129.7 (2C), 128.8,
128.4, 128.3, 128.2, 127.3, 127.1, 126.6, 126.5, 124.6, 123.0, 122.7,
121.9, 121.4, 119.8, 119.4, 113.7, 111.3, 77.3, 67.3, 59.0, 54.4, 52.8, 32.8,
21.4, 20.8. Anal. Calcd for C42H37BrClN3O3S$EtOAc: C, 63.70; H, 5.23;
N, 5.06. Found: C, 64.10; H, 5.60, N, 5.06.
4.3.1.2. Compound 2a. Rf¼0.5 (5% EtOAc/toluene); IR 3159,
3022, 2988, 2363, 2333, 1792, 1470, 1457, 1377 cm1; 1H NMR
(400 MHz) d 7.99 (d, J¼8.3 Hz, 1H), 7.74 (d, J¼8.3 Hz, 2H), 7.44 (d,
J¼7.4 Hz, 1H), 7.39e7.13 (m, 17H), 4.74 (d, J¼13.5 Hz, 1H), 4.55 (d,
J¼13.5 Hz, 1H), 4.13e4.02 (m, 2H), 3.95 (d, J¼13.6 Hz, 1H), 3.85 (d,
J¼11.8 Hz, 1H), 3.57e3.44 (m, 2H), 3.21 (br s, 1H), 2.88e2.70 (m,
2H), 2.34 (s, 3H), 2.16e2.01 (m, 1H), 2.00e1.85 (m, 1H); 13C NMR
(100 MHz) d 150.6, 144.7, 138.5, 138.1, 136.5, 135.3, 135.2, 131.2,
130.9, 129.8, 128.9, 128.5, 128.4, 128.0, 127.4, 127.2, 126.8, 126.6,
124.6, 123.2, 123.1, 123.0, 122.5, 121.9, 119.3, 117.0, 113.8, 110.8, 67.0,
64.7, 58.5, 57.1, 54.6, 30.5, 21.5, 19.8. Anal. Calcd for
C42H37BrClN3O3S$H2O: C, 63.28; H, 4.93; N, 5.27. Found: C, 63.21; H,
4.99; N, 5.20.
4.3.2. 1,3-Dibenzyl-7-bromo-9-chloro-5-phenethyl-2,3,4,5-
tetrahydro-1H-chromeno[4,3-d]pyrimidine (1b) and 1,3-dibenzyl-7-
bromo-9-chloro-4-phenethyl-2,3,4,5-tetrahydro-1H-chromeno[4,3-d]
pyrimidine (2b). Chroman-4-one 5b (0.100 g, 0.275 mmol) was
reacted with N-methylenebenzylamine19 (0.163 g, 1.37 mmol) and
L-proline (9.44 mg, 0.082 mmol) according to the general pro-
cedure. Puriﬁcation by ﬂash chromatography using EtOAc/heptane
(5:95/4:6) followed by toluene/heptane (3:7/1:1) as eluents
gave 1b (42 mg, 26%) and 2b (42 mg, 26%) as yellow oils.
4.3.2.1. Compound 1b. Rf¼0.7 (10% EtOAc/hexane); IR 3159,
3020, 2364, 2337, 1689, 1454 cm1; 1H NMR (400 MHz) d 7.39e7.15
(m, 17H), 4.68e4.61 (m, 1H), 4.03e3.92 (m, 2H), 3.55e3.48 (m, 3H),
3.26e3.12 (m, 2H), 3.00e2.91 (m, 2H), 2.83e2.75 (m, 1H),
2.09e2.00 (m, 1H), 1.82e1.74 (m, 1H); 13C NMR (100 MHz) d 148.4,
141.2, 138.3, 137.7, 134.6, 131.2, 128.8, 128.6, 128.5, 128.5, 128.4,
128.3, 127.3, 127.2, 126.5, 126.0, 122.7, 121.4, 119.9, 111.4, 77.5, 67.4,
59.1, 54.5, 52.8, 35.2, 31.7; HRMS (Q-TOF-MS) [MþH]þ, calcd for
C33H31BrClN2O: 585.1308, found: 585.1320.
4.3.2.2. Compound 2b. Rf¼0.6 (10% EtOAc/hexane); IR 3156,
3083, 3067, 3027, 2931, 2362, 2335, 1700 cm1; 1H NMR (400 MHz)
d 7.39e7.13 (m,17H), 4.82 (d, J¼13.4 Hz, 1H), 4.65 (d, J¼13.4 Hz, 1H),
4.06e3.91 (m, 3H), 3.80 (d, J¼11.6 Hz, 1H), 3.51e3.40 (m, 2H),
3.24e3.20 (m, 1H), 2.91e2.68 (m, 2H), 2.16e2.05 (m, 1H), 1.97e1.86
(m, 1H); 13C NMR (100 MHz) d 150.5, 142.3, 138.7, 138.1, 136.3, 131.1,
128.9, 128.5, 128.42 (2C), 128.40, 128.1, 127.2, 127.1, 126.7, 125.8,
123.1, 121.8, 117.6, 110.7, 67.0, 64.7, 58.7, 56.8, 54.6, 33.0, 30.7; HRMS
M. Friden-Saxin et al. / Tetrahedron 68 (2012) 7035e70407040(Q-TOF-MS) [MþH]þ, calcd for C33H31BrClN2O: 585.1308, found:
585.1309.
4.3.3. 1,3-Dibenzyl-7-bromo-9-chloro-5-methyl-2,3,4,5-tetrahydro-
1H-chromeno[4,3-d]pyrimidine (1c) and 1,3-dibenzyl-7-bromo-9-
chloro-4-methyl-2,3,4,5-tetrahydro-1H-chromeno[4,3-d]pyrimidine
(2c). Chroman-4-one 5c (0.100 g, 0.363 mmol) was reacted with N-
methylenebenzylamine19 (0.216 g, 1.82 mmol) and L-proline
(12.5 mg, 0.109 mmol) according to the general procedure. Puriﬁ-
cation by ﬂash chromatography using EtOAc/heptane (5/40%)
followed by toluene as the eluent afforded 1c (27 mg, 15%) and 2c
(41 mg, 23%) as yellow oils.
4.3.3.1. Compound 1c. Rf¼0.5 (10% EtOAc/toluene); IR 3161,
3081, 3030, 2363, 2338, 1692, 1457 cm1; 1H NMR (400 MHz)
d 7.40e7.18 (m, 12H), 4.88 (q, J¼6.5 Hz, 1H), 4.01e3.91 (m, 2H),
3.56e3.47 (m, 3H), 3.34 (d, J¼11.0 Hz, 1H), 3.18 (d, J¼16.8 Hz, 1H),
3.06 (d, J¼16.8 Hz, 1H), 1.39 (d, J¼6.5 Hz, 3H); 13C NMR (100 MHz)
d 148.7, 138.3, 134.3, 131.1, 128.9, 128.5 (2C), 128.4 (2C), 128.3, 127.4,
127.1, 126.3, 121.3, 111.3, 99.9, 74.7, 67.3, 59.1, 54.5, 52.6, 19.4. Anal.
Calcd for C26H24BrClN2O$0.5H2O: C, 61.86; H, 4.99; N, 5.55. Found:
C, 61.91; H, 5.24; N, 5.49.
4.3.3.2. Compound 2c. Rf¼0.7 (5% EtOAc/toluene); IR 3159,
3074, 3028, 2973, 2930, 2826, 2359, 2336,1651,1559 cm1; 1H NMR
(400 MHz) d 7.51e6.99 (m, 12H), 4.83 (d, J¼13.3 Hz, 1H), 4.64 (d,
J¼13.3 Hz, 1H), 3.93e3.84 (m, 2H), 3.76 (d, J¼13.6 Hz, 1H), 3.67 (d,
J¼11.4 Hz, 1H), 3.53 (d, J¼13.6 Hz, 1H), 3.41e3.26 (m, 2H), 1.26 (d,
J¼6.5 Hz, 3H); 13C NMR (100 MHz) d 150.4, 138.7, 138.3, 135.1, 131.1,
128.9, 128.5, 128.4, 127.2, 127.1, 126.7, 123.4, 121.8, 120.6, 110.5, 99.9,
67.6, 63.1, 55.3, 54.3, 54.2, 16.0. HRMS (Q-TOF-MS) [MþH]þ, calcd
for C26H2577BrClN2O: 495.0839, found: 495.0836.
4.4. Conformational analysis of general type VIII b-turns and
derivatives 6 and 2a
For evaluation of the potential applicability of these novel ring
systems as peptidomimetics their most stable conformations were
compared to that of various b-turn conformations of peptides. An
initial analysis indicated that the tricyclic ring systems of 1a and 2a
mimic a type VIII b-turn. The conformational analyses were made
on simpliﬁed structures of 1 denoted 6 (Fig. 6) and 2 (not shown)
with methyl groups as substituents in the 5- and 7-positions,
mimicking the possible orientation of attached chains. One nitro-
gen atom in the tetrahydropyrimidine ring was acetylated to cor-
respond to the N-terminus of a peptide and the C-terminal was
methylamidated. A low energy conformation of the novel ring
system in 6 obtained from the NAMFIS calculations was aligned
with an energy minimized type VIII b-turn with the amino acid
sequence AceGly-Ala-Ala-GlyeNHMe as shown in Fig. 6.31,32 The
dihedral angles of the b-turn VIII was constrained according to
previously deﬁned angles (F(iþ1)¼60, j(iþ1)¼30, F(iþ2)¼120
and j(iþ2)¼120).31 The type VIII b-turn of the peptide was energy
minimized using OPLS-2005 as the force ﬁeld in a simulated water
environment. The PRCG method was used with 500 iterations.
4.5. X-ray diffraction
Crystals of 1a were obtained by recrystallization from EtOAc/
hexane (1:1). The crystal structure determination was carried out on
a Rigaku Saturn CCD area detectorwith graphitemonochromatedMo
Ka radiation (l¼0.71073A) using c and q scans.33 The data were cor-
rected for Lorentz and polarization effects. The structure was solved
by direct methods and was reﬁned by full-matrix least-squares on
F.34,35 Hydrogen atoms were reﬁned using the riding model. The
crystal data and experimental parameters are summarized inSupplementary data. Crystallographic data (excluding structure fac-
tors) for the structure 1a in this paper have been deposited with the
Cambridge Crystallographic Data Centre as supplementary publica-
tion CCDC 838242. Copies of the data can be obtained, free of charge,
on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax:
þ44 (0)1223 336033 or e-mail: deposit@ccdc.cam.ac.uk].
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